1681 related articles for article (PubMed ID: 28784671)
21. Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS).
Kritikos A; Neofytos D; Khanna N; Schreiber PW; Boggian K; Bille J; Schrenzel J; Mühlethaler K; Zbinden R; Bruderer T; Goldenberger D; Pfyffer G; Conen A; Van Delden C; Zimmerli S; Sanglard D; Bachmann D; Marchetti O; Lamoth F;
Clin Microbiol Infect; 2018 Nov; 24(11):1214.e1-1214.e4. PubMed ID: 29909005
[TBL] [Abstract][Full Text] [Related]
22. Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.
Denardi LB; Keller JT; Oliveira V; Mario DAN; Santurio JM; Alves SH
Mycopathologia; 2017 Oct; 182(9-10):819-828. PubMed ID: 28493006
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals.
Eddouzi J; Parker JE; Vale-Silva LA; Coste A; Ischer F; Kelly S; Manai M; Sanglard D
Antimicrob Agents Chemother; 2013 Jul; 57(7):3182-93. PubMed ID: 23629718
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020).
Carvalhaes CG; Klauer AL; Rhomberg PR; Pfaller MA; Castanheira M
J Clin Microbiol; 2022 Apr; 60(4):e0244921. PubMed ID: 35249367
[TBL] [Abstract][Full Text] [Related]
25. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance.
Chowdhary A; Prakash A; Sharma C; Kordalewska M; Kumar A; Sarma S; Tarai B; Singh A; Upadhyaya G; Upadhyay S; Yadav P; Singh PK; Khillan V; Sachdeva N; Perlin DS; Meis JF
J Antimicrob Chemother; 2018 Apr; 73(4):891-899. PubMed ID: 29325167
[TBL] [Abstract][Full Text] [Related]
26. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology and Antifungal Susceptibility of
Badiee P; Boekhout T; Haddadi P; Mohammadi R; Ghadimi-Moghadam A; Soltani J; Zarei Mahmoudabadi A; Ayatollahi Mousavi SA; Najafzadeh MJ; Diba K; Salimi-Khorashad AR; Amin Shahidi M; Ghasemi F; Jafarian H
Microbiol Spectr; 2022 Dec; 10(6):e0245322. PubMed ID: 36445122
[TBL] [Abstract][Full Text] [Related]
28.
Arendrup MC; Jørgensen KM; Hare RK; Chowdhary A
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844005
[TBL] [Abstract][Full Text] [Related]
29. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology and antifungal susceptibilities of yeast isolates causing invasive infections across urban Beijing, China.
Guo LN; Xiao M; Cao B; Qu F; Zhan YL; Hu YJ; Wang XR; Liang GW; Gu HT; Qi J; Yuan H; Min R; Wang FY; Liu LJ; Wang HB; Jiang W; Duan XG; Xu WJ; Yu YH; Su JR; Zhang JZ; Nong JQ; Liu SM; Li J; Liu JT; Yue ZG; Yang D; Guo J; Zhao R; Zhang YN; Yang XM; Liu XQ; Hsueh PR; Xu YC
Future Microbiol; 2017 Sep; 12():1075-1086. PubMed ID: 28836465
[TBL] [Abstract][Full Text] [Related]
31. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
[TBL] [Abstract][Full Text] [Related]
32. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
[TBL] [Abstract][Full Text] [Related]
33. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation of echinocandin and azole treatments led to the disappearance of an FKS alteration but not azole resistance during clonal Candida glabrata persistent candidaemia.
Imbert S; Castain L; Pons A; Jacob S; Meyer I; Palous M; Vezinet C; Langeron O; Hennequin C; Monsel A; Fekkar A
Clin Microbiol Infect; 2016 Oct; 22(10):891.e5-891.e8. PubMed ID: 27484020
[TBL] [Abstract][Full Text] [Related]
35. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and Antifungal Susceptibility of the Emerging Fungal Species,
Sikora M; Kuthan R; Piskorska-Malolepsza K; Golas-Pradzynska M; Domański D; Augustynowicz-Kopeć E; Swoboda-Kopec E
Pol J Microbiol; 2019 Sep; 68(3):303-308. PubMed ID: 31880875
[TBL] [Abstract][Full Text] [Related]
37. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of azole resistance among clinical isolates of Candida glabrata in Poland.
Szweda P; Gucwa K; Romanowska E; Dzierz Anowska-Fangrat K; Naumiuk Ł; Brillowska-Da Browska A; Wojciechowska-Koszko I; Milewski S
J Med Microbiol; 2015 Jun; 64(6):610-619. PubMed ID: 25818698
[TBL] [Abstract][Full Text] [Related]
39. Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in
Espinel-Ingroff A; Turnidge J; Alastruey-Izquierdo A; Botterel F; Canton E; Castro C; Chen YC; Chen Y; Chryssanthou E; Dannaoui E; Garcia-Effron G; Gonzalez GM; Govender NP; Guinea J; Kidd S; Lackner M; Lass-Flörl C; Linares-Sicilia MJ; López-Soria L; Magobo R; Pelaez T; Quindós G; Rodriguez-Iglesia MA; Ruiz MA; Sánchez-Reus F; Sanguinetti M; Shields R; Szweda P; Tortorano A; Wengenack NL; Bramati S; Cavanna C; DeLuca C; Gelmi M; Grancini A; Lombardi G; Meletiadis J; Negri CE; Passera M; Peman J; Prigitano A; Sala E; Tejada M
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323038
[TBL] [Abstract][Full Text] [Related]
40. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.
Castanheira M; Messer SA; Jones RN; Farrell DJ; Pfaller MA
Int J Antimicrob Agents; 2014 Oct; 44(4):320-6. PubMed ID: 25129315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]